» Authors » F Mattner

F Mattner

Explore the profile of F Mattner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 54
Citations 962
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mardiko A, Buer J, Koster A, Kaba H, Mattner F, Zweigner J, et al.
J Hosp Infect . 2023 Apr; 137:35-43. PMID: 37061047
Background: In contrast to the beginning of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), pandemic, more and more hospital issues are now regulated by policy. Aim: To identify differences between...
2.
Mardiko A, Heinemann S, Bludau A, Kaba H, Leha A, von Maltzahn N, et al.
J Hosp Infect . 2022 May; 126:87-92. PMID: 35623468
Background: SARS-CoV-2 vaccination for healthcare workers (HCWs) started in Germany in December 2020. Hospitals had little time to prepare a vaccination strategy. Aim: To gather information on the initial vaccination...
3.
Bludau A, Heinemann S, Mardiko A, Kaba H, Leha A, von Maltzahn N, et al.
J Hosp Infect . 2022 Apr; 125:28-36. PMID: 35413422
Background: Patients are at risk of nosocomial COVID-19 infection. The role of accompanying persons/visitors as potential infection donors is not yet well researched, but the risk will be influenced by...
4.
5.
Messler S, Klare I, Wappler F, Werner G, Ligges U, Sakka S, et al.
J Hosp Infect . 2018 Nov; 101(3):264-271. PMID: 30408504
Background: Vancomycin-resistant Enterococcus faecium (VRE) is emerging in German intensive care units (ICUs). On a 32-bed surgical ICU at a university hospital, increasing numbers of nosocomial cases occurred despite enforcement...
6.
Schwarz C, Schulte-Hubbert B, Bend J, Abele-Horn M, Baumann I, Bremer W, et al.
Pneumologie . 2018 May; 72(5):347-392. PMID: 29758578
Cystic Fibrosis (CF) is the most common autosomal-recessive genetic disease affecting approximately 8000 people in Germany. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)...
7.
Schneeberger A, Hendrix S, Mandler M, Ellison N, Burger V, Brunner M, et al.
J Prev Alzheimers Dis . 2017 Dec; 2(2):103-114. PMID: 29231230
Objectives: The primary objective of this clinical trial was to assess the clinical activity of various doses and formulations of AFFITOPE® AD02 following its repeated s.c. administration to patients with...
8.
Eberl S, Katsifis A, Peyronneau M, Wen L, Henderson D, Loch C, et al.
Eur J Nucl Med Mol Imaging . 2016 Oct; 44(2):296-307. PMID: 27699720
Purpose: To determine the metabolic profiles of the translocator protein ligands PBR102 and PBR111 in rat and human microsomes and compare their in vivo binding and metabolite uptake in the...
9.
10.
Hendrix S, Ellison N, Stanworth S, Tierney L, Mattner F, Schmidt W, et al.
J Prev Alzheimers Dis . 2016 Feb; 2(2):91-102. PMID: 26866015
Background: Optimized scales and composite outcomes have been proposed as a way to more accurately measure Alzheimer's disease related decline. AFFITOPE® AD02, is an amyloid-beta (Aβ)-targeting vaccine to elicit anti-Aβ...